Product Code: GVR-4-68040-263-1
Blood Typing Market Growth & Trends:
The global blood typing market size is anticipated to reach USD 3.83 billion by 2030 and is projected to grow at a CAGR of 10.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is fueled by the increasing usage of blood group typing in forensic sciences and prenatal testing, alongside the rising number of blood transfusions necessitated by road accidents and emergencies.
Blood group typing is a critical process that identifies the O, A, B, and AB groups, ensuring compatibility between donors and recipients and determining the Rh factor. This is particularly crucial in prenatal testing to prevent Hemolytic Disease of the Newborn (HDN), a condition that can be fatal if not detected. The market's growth is also supported by the growing number of road accidents and emergencies, which necessitate transfusions, and the increasing number of donations.
According to CDC, road accidents claim approximately 1.35 million lives annually, highlighting the critical role of blood group typing in ensuring safe transfusions. The advanced medical infrastructure in many countries, including increased storage capacities in hospitals, further supports the market's growth by facilitating the storage and availability of blood samples for typing and cross-matching. The rise in accidents and trauma cases requiring blood transfusions is another key factor for the market growth. The urgent need for transfusion in patients requiring surgical intervention also acts as a key driving factor.
Furthermore, prenatal testing, which requires blood group typing to manage potential complications, is another significant driver. The need for accurate blood group typing in pregnant women to prevent HDN is anticipated to further drive the market's growth. In addition, the increasing demand for blood group typing in forensic sciences contributes to the market's expansion.
Moreover, market players are striving to innovate and introduce new initiatives that contribute to the advancement of diagnostic technologies. These initiatives play a pivotal role in shaping the dynamics of the market, driving improvements in patient care, and addressing the evolving needs of healthcare providers. By leveraging their expertise and resources, market players introduce innovative solutions that enhance efficiency, accuracy, and accessibility within the healthcare ecosystem. For instance, in March 2022, Quotient Limited obtains CE Mark for MosaiQ Extended Immunohematology Microarray, enhancing blood typing capabilities with Antibody Screening, Antigen Typing, and ABO grouping on a single platform, promising improved workflow and clinical value. Such initiatives market players contribute to the broader healthcare market, with a focus on advancements in diagnostic technologies.
Blood Typing Market Report Highlights:
- The reagents and consumables segment led the market with the largest revenue share of 71.7% in 2023 and is anticipated to grow at the lucrative CAGR over the forecast period, owing to extensive R&D initiatives being undertaken by major players for development of novel kits
- Based on test type, the antibody screening segment led the market with the largest revenue share of 38.6% in 2023, whereas HLA typing segment is estimated to grow at the fastest CAGR over the forecast period, owing to the development of advanced and innovative diagnostics in the market
- Based on technique, the PCR based and microarray based segment led the market with the largest revenue share of 52.1% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period
- Based on application, the diagnostic testing segment led the market with the largest revenue share of 54.1% in 2023. The organ transplants segment is estimated to grow at the fastest CAGR over the forecast period
- Based on end-use, the diagnostic laboratories segment led the market with the largest revenue share of 43.4% in 2023, owing to large number of tests being done at the facilities
- North America dominated the market with the revenue share of 44.6% in 2023, owing to factors such as advanced healthcare infrastructure, rising prevalence of chronic diseases, and favorable regulatory environment
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product & Services
- 1.2.2. Test Type
- 1.2.3. Technique
- 1.2.4. Application
- 1.2.5. End-use
- 1.2.6. Regional scope
- 1.2.7. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product & services outlook
- 2.2.2. Test type outlook
- 2.2.3. Technique outlook
- 2.2.4. Application outlook
- 2.2.5. End-use outlook
- 2.2.6. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Blood Typing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing demand for blood group typing in prenatal testing
- 3.2.1.2. Growing number of road accidents, emergencies, and trauma cases necessitating transfusions
- 3.2.1.3. Rising number of blood donations
- 3.2.2. Market restraint analysis
- 3.2.2.1. Poor blood service infrastructure
- 3.2.2.2. Lack of awareness and skilled professionals
- 3.3. Blood Typing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.4. Pricing Analysis
Chapter 4. Blood Typing Market: Product & Services Estimates & Trend Analysis
- 4.1. Blood Typing Market: Product & Services Dashboard
- 4.2. Global Blood Typing Market Movement Analysis
- 4.3. Global Blood Typing Market by Product & Services Outlook
- 4.4. Instruments
- 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Reagents & Consumables
- 4.5.1. Reagents & consumables market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5.1.1. RBC reagents
- 4.5.1.1.1. RBC Reagents Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5.1.2. Antisera reagents
- 4.5.1.2.1. Antisera Reagents Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5.1.3. Anti-Human Globulin Reagents
- 4.5.1.3.1. Anti-Human Globulin Reagents Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5.1.4. Blood Saline Reagents
- 4.5.1.4.1. Blood Saline Reagents Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Services
- 4.6.1. Services market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Blood Typing Market: Test Type Estimates & Trend Analysis
- 5.1. Blood Typing Market: Test Type Dashboard
- 5.2. Global Blood Typing Market Movement Analysis
- 5.3. Global Blood Typing Market by Test Type Outlook
- 5.4. Antibody Screening
- 5.4.1. Antibody screening market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. HLA Typing
- 5.5.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Cross-Matching Tests
- 5.6.1. Cross-matching tests market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. ABO blood Tests
- 5.7.1. ABO blood tests market estimates and forecasts 2018 to 2030 (USD Million)
- 5.8. Others
- 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Blood Typing Market: Technique Estimates & Trend Analysis
- 6.1. Blood Typing Market: Technique Dashboard
- 6.2. Global Blood Typing Market Movement Analysis
- 6.3. Global Blood Typing Market by Technique Outlook
- 6.4. PCR based and Microarray based
- 6.4.1. PCR based and Microarray based market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Assay based techniques
- 6.5.1. Assay based techniques market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Massively Parallel Sequencing
- 6.6.1. Massively Parallel Sequencing market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. Others
- 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Blood Typing Market: Application Estimates & Trend Analysis
- 7.1. Blood Typing Market: Application Dashboard
- 7.2. Global Blood Typing Market Movement Analysis
- 7.3. Global Blood Typing Market by Application Outlook
- 7.4. Blood transfusions
- 7.4.1. Blood transfusions market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Organ transplants
- 7.5.1. Organ transplants market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Diagnostic testing
- 7.6.1. Diagnostic testing market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Blood Typing Market: End-use Estimates & Trend Analysis
- 8.1. Blood Typing Market: End-use Dashboard
- 8.2. Global Blood Typing Market Movement Analysis
- 8.3. Global Blood Typing Market by End-use Outlook
- 8.4. Hospitals & clinics
- 8.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5. Diagnostic laboratories
- 8.5.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6. Blood banks
- 8.6.1. Blood banks market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7. Others
- 8.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Blood Typing Market: Regional Estimates & Trend Analysis by Product & Services, Test Type, Technique, Application and End-use
- 9.1. Regional Dashboard
- 9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 9.3. North America
- 9.3.1. U.S.
- 9.3.1.1. Key country dynamics
- 9.3.1.2. Regulatory framework/ reimbursement structure
- 9.3.1.3. Competitive scenario
- 9.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 9.3.2. Canada
- 9.3.2.1. Key country dynamics
- 9.3.2.2. Regulatory framework/ reimbursement structure
- 9.3.2.3. Competitive scenario
- 9.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4. Europe
- 9.4.1. UK
- 9.4.1.1. Key country dynamics
- 9.4.1.2. Regulatory framework/ reimbursement structure
- 9.4.1.3. Competitive scenario
- 9.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.2. Germany
- 9.4.2.1. Key country dynamics
- 9.4.2.2. Regulatory framework/ reimbursement structure
- 9.4.2.3. Competitive scenario
- 9.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.3. France
- 9.4.3.1. Key country dynamics
- 9.4.3.2. Regulatory framework/ reimbursement structure
- 9.4.3.3. Competitive scenario
- 9.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.4. Italy
- 9.4.4.1. Key country dynamics
- 9.4.4.2. Regulatory framework/ reimbursement structure
- 9.4.4.3. Competitive scenario
- 9.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.5. Spain
- 9.4.5.1. Key country dynamics
- 9.4.5.2. Regulatory framework/ reimbursement structure
- 9.4.5.3. Competitive scenario
- 9.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.6. Norway
- 9.4.6.1. Key country dynamics
- 9.4.6.2. Regulatory framework/ reimbursement structure
- 9.4.6.3. Competitive scenario
- 9.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.7. Sweden
- 9.4.7.1. Key country dynamics
- 9.4.7.2. Regulatory framework/ reimbursement structure
- 9.4.7.3. Competitive scenario
- 9.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.8. Denmark
- 9.4.8.1. Key country dynamics
- 9.4.8.2. Regulatory framework/ reimbursement structure
- 9.4.8.3. Competitive scenario
- 9.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5. Asia Pacific
- 9.5.1. Japan
- 9.5.1.1. Key country dynamics
- 9.5.1.2. Regulatory framework/ reimbursement structure
- 9.5.1.3. Competitive scenario
- 9.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.2. China
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework/ reimbursement structure
- 9.5.2.3. Competitive scenario
- 9.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.3. India
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Regulatory framework/ reimbursement structure
- 9.5.3.3. Competitive scenario
- 9.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.4. Australia
- 9.5.4.1. Key country dynamics
- 9.5.4.2. Regulatory framework/ reimbursement structure
- 9.5.4.3. Competitive scenario
- 9.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.5. South Korea
- 9.5.5.1. Key country dynamics
- 9.5.5.2. Regulatory framework/ reimbursement structure
- 9.5.5.3. Competitive scenario
- 9.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.6. Thailand
- 9.5.6.1. Key country dynamics
- 9.5.6.2. Regulatory framework/ reimbursement structure
- 9.5.6.3. Competitive scenario
- 9.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6. Latin America
- 9.6.1. Brazil
- 9.6.1.1. Key country dynamics
- 9.6.1.2. Regulatory framework/ reimbursement structure
- 9.6.1.3. Competitive scenario
- 9.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6.2. Mexico
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework/ reimbursement structure
- 9.6.2.3. Competitive scenario
- 9.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6.3. Argentina
- 9.6.3.1. Key country dynamics
- 9.6.3.2. Regulatory framework/ reimbursement structure
- 9.6.3.3. Competitive scenario
- 9.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 9.7. MEA
- 9.7.1. South Africa
- 9.7.1.1. Key country dynamics
- 9.7.1.2. Regulatory framework/ reimbursement structure
- 9.7.1.3. Competitive scenario
- 9.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 9.7.2. Saudi Arabia
- 9.7.2.1. Key country dynamics
- 9.7.2.2. Regulatory framework/ reimbursement structure
- 9.7.2.3. Competitive scenario
- 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 9.7.3. UAE
- 9.7.3.1. Key country dynamics
- 9.7.3.2. Regulatory framework/ reimbursement structure
- 9.7.3.3. Competitive scenario
- 9.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 9.7.4. Kuwait
- 9.7.4.1. Key country dynamics
- 9.7.4.2. Regulatory framework/ reimbursement structure
- 9.7.4.3. Competitive scenario
- 9.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Recent Developments & Impact Analysis, By Key Market Participants
- 10.2. Company/Competition Categorization
- 10.3. Vendor Landscape
- 10.3.1. List of key distributors and channel partners
- 10.3.2. Key customers
- 10.3.3. Key company market share analysis, 2023
- 10.3.4. Mesa Laboratories, Inc. (Agena Bioscience, Inc.)
- 10.3.4.1. Company overview
- 10.3.4.2. Financial performance
- 10.3.4.3. Product benchmarking
- 10.3.4.4. Strategic initiatives
- 10.3.5. Danaher Corporation (Beckman Coulter)
- 10.3.5.1. Company overview
- 10.3.5.2. Financial performance
- 10.3.5.3. Product benchmarking
- 10.3.5.4. Strategic initiatives
- 10.3.6. Bio-Rad Laboratories, Inc
- 10.3.6.1. Company overview
- 10.3.6.2. Financial performance
- 10.3.6.3. Product benchmarking
- 10.3.6.4. Strategic initiatives
- 10.3.7. DIAGAST
- 10.3.7.1. Company overview
- 10.3.7.2. Financial performance
- 10.3.7.3. Product benchmarking
- 10.3.7.4. Strategic initiatives
- 10.3.8. Grifols, S.A.
- 10.3.8.1. Company overview
- 10.3.8.2. Financial performance
- 10.3.8.3. Product benchmarking
- 10.3.8.4. Strategic initiatives
- 10.3.9. AXO Science
- 10.3.9.1. Company overview
- 10.3.9.2. Financial performance
- 10.3.9.3. Product benchmarking
- 10.3.9.4. Strategic initiatives
- 10.3.10. Merck KGaA
- 10.3.10.1. Company overview
- 10.3.10.2. Financial performance
- 10.3.10.3. Product benchmarking
- 10.3.10.4. Strategic initiatives
- 10.3.11. Thermo Fisher Scientific
- 10.3.11.1. Company overview
- 10.3.11.2. Financial performance
- 10.3.11.3. Product benchmarking
- 10.3.11.4. Strategic initiatives
- 10.3.12. Immucor, Inc.
- 10.3.12.1. Company overview
- 10.3.12.2. Financial performance
- 10.3.12.3. Product benchmarking
- 10.3.12.4. Strategic initiatives
- 10.3.13. BAG Diagnostics GmbH
- 10.3.13.1. Company overview
- 10.3.13.2. Financial performance
- 10.3.13.3. Product benchmarking
- 10.3.13.4. Strategic initiatives
- 10.3.14. Seegene Inc.
- 10.3.14.1. Company overview
- 10.3.14.2. Financial performance
- 10.3.14.3. Product benchmarking
- 10.3.14.4. Strategic initiatives